Hrishikesh Samant, MD
Gastroenterology · Shreveport, LANPI 1982087755
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,228 of the $80,869 with a category attached, or 78.2%. 23 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 48.6% of the total. 2025 is the largest year on record at $65,457, more than ten times the $731 reported in 2019. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $502.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$39K
- Madrigal Pharmaceuticals$26K
- Fujifilm Healthcare Americas Corporation$4K
- Mirum Pharmaceuticals, Inc.$3K
- Orphalan Inc$3K
- Intercept Pharmaceuticals, Inc.$2K
- plus $3K from 17 others
What the payments were for
- Consulting fees$6,2328%
- Speaking & faculty fees$63,22878%
- Travel & lodging$6,5758%
- Food & beverage$4,7566%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 18 | $39,268 |
| Madrigal Pharmaceuticals | 34 | $25,870 |
| Fujifilm Healthcare Americas Corporation | 3 | $3,810 |
| Mirum Pharmaceuticals, Inc. | 6 | $3,413 |
| Orphalan Inc | 3 | $3,115 |
| Intercept Pharmaceuticals, Inc. | 5 | $2,260 |
| Eton Pharmaceuticals, Inc. | 1 | $1,025 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $582 |
| AbbVie | 21 | $510 |
| Gilead | 8 | $273 |
| AstraZeneca | 7 | $180 |
| Dova Pharmaceuticals | 7 | $157 |
| Novo Nordisk | 2 | $147 |
| Eisai Inc. | 1 | $77 |
| Pfizer | 2 | $31 |
| Shionogi Inc | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Medtronic | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IQIRVO$38,942
- REZDIFFRA$24,138
- uTASWako AFP-L3$3,778
- CUVRIOR$3,000
- OCALIVA$2,200
- GALZIN$1,025
- CARGLUMIC ACID$1,025
- BETAINE ANHYDROUS$1,025
- NITISINONE$1,025
- Wegovy$115
- Mavyret$115
How this compares
$80,869 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 73 | $234,875 |
| OcalivaObeticholic Acid | 14 | $118,561 |
| VemlidyTenofovir Alafenamide | 28 | $40,594 |
| Tacrolimus | 139 | $12,212 |
| Entecavir | 27 | $8,064 |
| LinzessLinaclotide | 11 | $7,736 |
| Ursodiol | 43 | $4,255 |
| Mycophenolate Mofetil | 56 | $3,213 |
| Sirolimus | 16 | $2,820 |
| Pantoprazole Sodium | 246 | $2,003 |
| Tenofovir Disoproxil Fumarate | 18 | $1,781 |
| Spironolactone | 91 | $1,409 |
| Azathioprine | 22 | $924 |
| Lactulose | 28 | $857 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 11 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $582 | $234,87573 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $2,260 | $118,56114 claims |
| GileadVemlidy | $273 | $40,59428 claims |
| AbbVieLinzess | $510 | $7,73611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Shreveport
- Humberto AguilarShreveport$313K
- Sathya JaganmohanShreveport$25K
- Qiang CaiShreveport$14K
- Elvin HardyShreveport$13K
- James MorrisShreveport$11K
- John ProvenzaShreveport$9K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.